Search research articles
Contact Us
Filters
Showing results (31-40 of 70) with videos related to
Page
of 7
Sort By:
Gynecologic Oncology
|
April 26, 2011
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
S John Weroha, Ann L Oberg, Katie L Allen Ziegler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2014
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors
Paul Haluska, Michael Menefee, Elizabeth R Plimack, et al.
Breast Cancer Research and Treatment
|
April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
Cynthia X Ma, Vera J Suman, Matthew Goetz, et al.
Gynecologic Oncology
|
May 3, 2017
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers
Gerardo Colon-Otero, S John Weroha, Nathan R Foster, et al.
Gynecologic Oncology
|
November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
Andrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Cancer Chemotherapy and Pharmacology
|
January 7, 2014
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
Daruka Mahadevan, Gregory Ryan Sutton, Rafael Arteta-Bulos, et al.
Cancer Research
|
October 1, 2009
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro
Andrea E Wahner Hendrickson, Paul Haluska, Paula A Schneider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
Paul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
Molecular Cancer Therapeutics
|
January 12, 2011
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924
Xiaonan Hou, Fei Huang, Joan M Carboni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer
Daniel D Karp, Luis G Paz-Ares, Silvia Novello, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 70) with videos related to
Sort By:
Page
of 7
Gynecologic Oncology
|
April 26, 2011
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
S John Weroha, Ann L Oberg, Katie L Allen Ziegler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2014
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors
Paul Haluska, Michael Menefee, Elizabeth R Plimack, et al.
Breast Cancer Research and Treatment
|
April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
Cynthia X Ma, Vera J Suman, Matthew Goetz, et al.
Gynecologic Oncology
|
May 3, 2017
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers
Gerardo Colon-Otero, S John Weroha, Nathan R Foster, et al.
Gynecologic Oncology
|
November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
Andrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Cancer Chemotherapy and Pharmacology
|
January 7, 2014
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
Daruka Mahadevan, Gregory Ryan Sutton, Rafael Arteta-Bulos, et al.
Cancer Research
|
October 1, 2009
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro
Andrea E Wahner Hendrickson, Paul Haluska, Paula A Schneider, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
Paul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
Molecular Cancer Therapeutics
|
January 12, 2011
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924
Xiaonan Hou, Fei Huang, Joan M Carboni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer
Daniel D Karp, Luis G Paz-Ares, Silvia Novello, et al.
Page
of 7